- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01213966
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection
연구 개요
상세 설명
This exploratory Phase IIa study aims to investigate the preliminary efficacy in terms of parasite reduction and clearance in malaria patients, and the tolerability of OZ439 administered as single dose regimen at 3 different doses in parallel cohorts of patients with either acute uncomplicated Plasmodium falciparum or Plasmodium vivax malaria mono-infection (10 patients per plasmodium species per dose level).
Treatment with OZ439 will be given as a single dose on Day 0, starting in the first cohort at a dose of 800 mg. Established antimalarial therapy will be given at the latest at 36 hours post dosing.
The primary endpoint will be the derived parasite reduction rate (PRR) at 24 hours after study drug administration.
A review of each individual study cohort (dose/species) will be conducted with the Principal Investigator and the Sponsor and a decision will be reached on whether the dose for the next cohort should increase or decrease (within 200mg-1600mg range). This decision will be based on parasite reduction rate over the first 24 hours following administration of OZ439, tolerability and exposure.
연구 유형
등록 (실제)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female patients between the age of 18 and 60 years, inclusive
- Body weight between 40 kg and 90 kg inclusive
Presence of mono-infection of P. falciparum or P. vivax confirmed by:
- Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,
- Microscopically confirmed parasite infection, 5,000 to 50,000 asexual parasite count/µl of blood
- Written informed consent, in accordance with local practice, provided by patient. If the patient is unable to write, witnessed consent is permitted according to local ethical considerations
- Ability to swallow oral medication
- Ability and willingness to participate and access the health facility
- Agree to minimum of 4 days hospitalisation for drug administration and pharmacokinetic sampling
Exclusion Criteria:
- Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organisation Criteria 2010 (Attachment 2)
- Mixed Plasmodium infection
- Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day
- Presence of other serious or chronic clinical condition requiring hospitalisation.
- Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS/WHO normalised reference values).
- Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater than or equal to 450 msec), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including head trauma).
- Known history of hypersensitivity, allergic or adverse reactions to artemisinin containing compounds or mefloquine or drug in the national guidelines for P. vivax.
- Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).
- Have received any antimalarial treatment in the preceding 14 days, as determined by history and screening test.
- Have received antibacterial with known antimalarial activity in the preceding 14 days.
- Have received an investigational drug within the past 4 weeks.
- Liver function tests (ASAT/ALAT levels) more than 2 x ULN
- Hb level below 10 g/dL.
- Bilirubin levels greater than 40 µmol/L.
- Serum creatinine levels more than 2 times the upper limit of normal range in absence of dehydration. In case of important dehydration the creatinine should be lower than 2X ULN after oral/parenteral rehydration.
- Female patients must be neither pregnant (as demonstrated by a negative serum pregnancy test) nor lactating, and must be willing to take measures not to become pregnant during the study period and safety follow-up period
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: 800 mg OZ439 po single dose
|
po, single dose
다른 이름들:
|
실험적: 400 mg OZ439 p.o. single dose
|
po, single dose
다른 이름들:
|
실험적: 200mg OZ439 p.o. single dose
|
po, single dose
다른 이름들:
|
실험적: 1200 mg OZ439 po single dose
|
po, single dose
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Derived Parasite Reduction Rate at 24 Hours (PPR24)
기간: 24 hours after study drug administration
|
PRR24 is the log10 change in parasitemia over 24 hours estimated from a regression model fit separately for each patient. The relationship between parasite counts and time was analyzed by fitting a variable lag phase, then a linear decline to the natural log of parasite count versus time relationship. The slope of this log linear relationship is the primary end-point. The time points chosen for the regression are those that yield the highest degree of significance when assessing the regression when the number of time points are greater than or equal to 3. No extrapolation was performed. |
24 hours after study drug administration
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- MMV_OZ439_10_002
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
말라리아, 팔시파룸에 대한 임상 시험
-
Novartis Pharmaceuticals모병복잡하지 않은 Plasmodium Falciparum 말라리아코트디부아르, 케냐, 가나, 우간다
-
Medicines for Malaria Venture완전한복잡하지 않은 Plasmodium Falciparum 말라리아우간다, 베냉, 부키 나 파소, 콩고 민주 공화국, 가봉, 모잠비크, 베트남
-
Karolinska University HospitalMuhimbili University of Health and Allied Sciences완전한
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical Research...모병
-
Jomaa Pharma GmbHCentre de Recherche Médicale de Lambaréné알려지지 않은단순 급성 Plasmodium Falciparum 말라리아의 경구 치료
-
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.PATH; World Health Organization; Xinhua Hospital, Shanghai Jiao Tong University School of... 그리고 다른 협력자들완전한
-
Muhimbili University of Health and Allied SciencesUppsala University; The Swedish Research Council아직 모집하지 않음
-
Novartis PharmaceuticalsEuropean and Developing Countries Clinical Trials Partnership (EDCTP)모병복잡하지 않은 Plasmodium Falciparum 말라리아부키 나 파소, 말리, 가봉
-
David SaundersNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; Royal Cambodian... 그리고 다른 협력자들정지된
-
University of Oxford아직 모집하지 않음복잡하지 않은 Plasmodium Falciparum 말라리아
OZ439에 대한 임상 시험
-
Medicines for Malaria Venture완전한
-
Medicines for Malaria VentureQuotient Clinical완전한
-
Medicines for Malaria VentureSyneos Health; Nucleus Network Ltd완전한
-
Medicines for Malaria VentureQuotient Clinical완전한
-
Medicines for Malaria VentureRichmond Pharmacology Limited완전한
-
Medicines for Malaria VentureQueensland Institute of Medical Research완전한
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; Queensland Institute of Medical...종료됨
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer Medical Research...완전한
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer Medical Research... 그리고 다른 협력자들완전한